valve

La revascularización incompleta se asocia a mortalidad en el TAVI

Low Risk Patients: TAVR with Self-Expanding Valves Offers Similar Outcomes to Surgery Based on a Bayesian Analysis?

When compared against surgical valve replacement (SAVR) transcatheter aortic valve replacement (TAVR) has shown benefits across different risk groups, not only in events as death and stroke, but also in quality of life (especially in the first months post procedure) and improved symptoms.&nbsp; However, a catch-up phenomenon was observed in low-risk patients between the first<a href="https://solaci.org/en/2022/03/17/low-risk-patients-tavr-with-self-expanding-valves-offers-similar-outcomes-to-surgery-based-on-a-bayesian-analysis/" title="Read more" >...</a>

¿Son las válvulas autoexpandibles una opción válida en las bicúspides?

Are Self-Expandable Valves a Valid Option in Bicuspids?

Bicuspid Aortic Valves (VAV) are challenging for TAVR given its anatomical characteristics and the important presence of calcification. However, current data are promising.&nbsp; Even though traditionally excluded from the larger randomized studies, self-expandable valves appear to have similar evolution to tricuspid aortic valves (TAV) with severe stenosis.&nbsp; Researchers looked at the Low-Risk Bicuspid Study and<a href="https://solaci.org/en/2022/03/16/are-self-expandable-valves-a-valid-option-in-bicuspids/" title="Read more" >...</a>

Sangrado y mortalidad en el reemplazo valvular aórtico por catéter

Are Expandable-Balloon Valves an Option for the Bicuspid Valve in Low-Risk Patients?

Bicuspid aortic valve malformation is the most frequent cardiac malformation (about 1%), and a significant percentage of these cases generate severe aortic stenosis. As we know, transcatheter aortic valve replacement (TAVR) has been developed for tricuspid valves, which are studied in the most important randomized trials for high-, medium-, and low-risk patients. While current information<a href="https://solaci.org/en/2022/03/16/are-expandable-balloon-valves-an-option-for-the-bicuspid-valve-in-low-risk-patients/" title="Read more" >...</a>

¿Fin de la discusión sobre el impacto del marcapaso post TAVI?

Is Cusp Overlapping Projection the New Self-Expandable Valve Implantation Technique?

In Europe and the US, aortic stenosis is the most frequent cause of valve intervention, both surgical and percutaneous, and, as we all know, TAVR has made great progress in this regard.&nbsp; However, this technique has an Achilles heel when it comes to self-expandable valves: definite pacemaker implantation rate is 3 to 4 times higher<a href="https://solaci.org/en/2022/03/11/is-cusp-overlapping-projection-the-new-self-expandable-valve-implantation-technique/" title="Read more" >...</a>

Enfermedad pulmonar y TAVI, solo se beneficia un grupo reducido de pacientes

Melody: One of the Pioneers in Transcatheter Pulmonary Valve Replacement with Long Term Outcomes

At 10 years of the Melody Investigational Device Exemption we can observe this device for transcatheter pulmonary valve replacement might be a lifetime fix, both to extend the useful life of previously implanted right ventricular outflow tract (RVOT) conduits or bioprosthetic pulmonary valves.&nbsp; Patient enrollment for the US Investigational Device Exemption study of the Melody<a href="https://solaci.org/en/2022/01/24/melody-one-of-the-pioneers-in-transcatheter-pulmonary-valve-replacement-with-long-term-outcomes/" title="Read more" >...</a>

Experiencia de la cirugía

TAVR vs Sutureless Surgical Aortic Valve Replacement in Low-Risk Patients

Sutureless surgical aortic valve replacement (SU-SAVR) has been designed to make surgical valve replacement easier and faster, especially compared against conventional biological valves which require multiple sutures; their rapid deployment translates into reduced cross-clamp and operative time. These valves shorten operating time and are less invasive than conventional surgical valves.&nbsp; Except for sternotomy incisions, they<a href="https://solaci.org/en/2021/11/19/tavr-vs-sutureless-surgical-aortic-valve-replacement-in-low-risk-patients/" title="Read more" >...</a>

TCT 2021 | SURTAVI: buenas noticias para la válvula autoexpandible a 5 años

TCT 2021 | SURTAVI: Good News for the Self-Expandable Valve at 5 Years

After a 5-year followup, the transcatheter aortic replacement (TAVR) with the self-expandable valve has offered clinical outcomes similar to surgical aortic valve replacement (SAVR) outcomes for intermediate risk patients.&nbsp; As we already knew form the 2-year followup, the all-cause or disabling stroke rate at 5 years between TAVR and SAVR continued to be similar (31.3%<a href="https://solaci.org/en/2021/11/09/tct-2021-surtavi-good-news-for-the-self-expandable-valve-at-5-years/" title="Read more" >...</a>

Trombólisis local en tromboembolismo pulmonar

Device Evolution Also Impacts on Valve in Valve

TAVR to treat dysfunctional biological prosthetics (ViV) with the last generation self-expandable supra-annular prosthetic offers excellent results both clinical and hemodynamic. In addition, there were additional reductions of paravalvular regurgitation compared against the original models.&nbsp; The present registry published in JAHA is the most extensive to treat this issue and replicate outcomes from the clinical<a href="https://solaci.org/en/2021/10/21/device-evolution-also-impacts-on-valve-in-valve/" title="Read more" >...</a>

valve_in_valve

Failed Aortic Bioprosthesis: Valve in Vale or Repeat Surgery?

The Valve in Valve (ViV) technique seems to be a better option than repeat surgery for failed aortic bioprosthesis. While this strategy lacks long-term evidence to address issues such as durability, it is considered as an option especially for young patients. ViV to treat failed surgical bioprosthesis has shown lower in-hospital mortality compared with repeat<a href="https://solaci.org/en/2021/10/20/failed-aortic-bioprosthesis-valve-in-vale-or-repeat-surgery/" title="Read more" >...</a>

Top